A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2010
This article has no abstract
Epistemonikos ID: 5f79868b47f9190600f174d53b771064b7498523
First added on: Mar 01, 2025